1
|
Czub N, Pacławski A, Szlęk J, Mendyk A. Curated Database and Preliminary AutoML QSAR Model for 5-HT1A Receptor. Pharmaceutics 2021; 13:pharmaceutics13101711. [PMID: 34684004 PMCID: PMC8536971 DOI: 10.3390/pharmaceutics13101711] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 10/13/2021] [Accepted: 10/14/2021] [Indexed: 11/23/2022] Open
Abstract
Introduction of a new drug to the market is a challenging and resource-consuming process. Predictive models developed with the use of artificial intelligence could be the solution to the growing need for an efficient tool which brings practical and knowledge benefits, but requires a large amount of high-quality data. The aim of our project was to develop quantitative structure–activity relationship (QSAR) model predicting serotonergic activity toward the 5-HT1A receptor on the basis of a created database. The dataset was obtained using ZINC and ChEMBL databases. It contained 9440 unique compounds, yielding the largest available database of 5-HT1A ligands with specified pKi value to date. Furthermore, the predictive model was developed using automated machine learning (AutoML) methods. According to the 10-fold cross-validation (10-CV) testing procedure, the root-mean-squared error (RMSE) was 0.5437, and the coefficient of determination (R2) was 0.74. Moreover, the Shapley Additive Explanations method (SHAP) was applied to assess a more in-depth understanding of the influence of variables on the model’s predictions. According to to the problem definition, the developed model can efficiently predict the affinity value for new molecules toward the 5-HT1A receptor on the basis of their structure encoded in the form of molecular descriptors. Usage of this model in screening processes can significantly improve the process of discovery of new drugs in the field of mental diseases and anticancer therapy.
Collapse
|
2
|
Giorgioni G, Del Bello F, Pavletić P, Quaglia W, Botticelli L, Cifani C, Micioni Di Bonaventura E, Micioni Di Bonaventura MV, Piergentili A. Recent findings leading to the discovery of selective dopamine D 4 receptor ligands for the treatment of widespread diseases. Eur J Med Chem 2020; 212:113141. [PMID: 33422983 DOI: 10.1016/j.ejmech.2020.113141] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 12/23/2020] [Accepted: 12/24/2020] [Indexed: 12/14/2022]
Abstract
Since its discovery, the dopamine D4 receptor (D4R) has been suggested to be an attractive target for the treatment of neuropsychiatric diseases. Novel findings have renewed the interest in such a receptor as an emerging target for the management of different diseases, including cancer, Parkinson's disease, alcohol or substance use disorders, eating disorders, erectile dysfunction and cognitive deficits. The recently resolved crystal structures of D4R in complexes with the potent ligands nemonapride and L-745870 strongly improved the knowledge on the molecular mechanisms involving the D4R functions and may help medicinal chemists in drug design. This review is focused on the recent development of the subtype selective D4R ligands belonging to classical or new chemotypes. Moreover, ligands showing functional selectivity toward G protein activation or β-arrestin recruitment and the effects of selective D4R ligands on the above-mentioned diseases are discussed.
Collapse
Affiliation(s)
- Gianfabio Giorgioni
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy.
| | - Pegi Pavletić
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Wilma Quaglia
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy.
| | - Luca Botticelli
- School of Pharmacy, Pharmacology Unit, University of Camerino, Via Madonna Delle Carceri 9, 62032, Camerino, Italy
| | - Carlo Cifani
- School of Pharmacy, Pharmacology Unit, University of Camerino, Via Madonna Delle Carceri 9, 62032, Camerino, Italy
| | | | | | - Alessandro Piergentili
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| |
Collapse
|
3
|
Chen W, Yang L, Yan C, Yao B, Lu J, Xu J, Liu G. Surface-Confined Building of Au@Pt-Centered and Multi-G-Quadruplex/Hemin Wire-Surrounded Electroactive Super-nanostructures for Ultrasensitive Monitoring of Morphine. ACS Sens 2020; 5:2644-2651. [PMID: 32633121 DOI: 10.1021/acssensors.0c01230] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Overuse and abuse of morphine (MOP), one of the main components of pericarpium papaveris, have attracted increasing attention in the medical field owing to its pharmacological and toxicological activity. Herein, we proposed a new electrochemical nano-biosensor for MOP detection based on surface-confined building of Au@Pt-centered and multi-G-quadruplex/hemin wire-surrounded electroactive super-nanostructures. The center Au@Pt was flower-shaped and irregularly protruded, allowing substantial loading of multiple G-quadruplex wire/hemin complexes on its surface to accomplish the assembly of electroactive super-nanostructures. Interestingly, as the super-nanostructures were closely confined on the electrode surface, a significantly amplified electrochemical signal was thus obtained in the absence of MOP. In contrast, the introduction of target MOP can induce an intense competitive effect and strongly destroy the assembly process, resulting in the reduction of the electrochemical response that is correlated with the logarithmic concentration of MOP. Under optimal conditions, the electrochemical nano-biosensor is capable of highly sensitive detection of MOP in a dynamic concentration range from 1 ppt to 500 ppb. The limit of detection is achieved as low as 0.69 ppt, and the practical application was confirmed by examining MOP from chafing dish condiments. We expect the electrochemical platform utilizing this unique nanoarchitecture to provide rational guidelines to design high-performance analytical tools.
Collapse
Affiliation(s)
- Wei Chen
- Engineering Research Center of Bioprocess, MOE, School of Food & Biological Engineering, Hefei University of Technology, Hefei 230009, China
| | - Lijun Yang
- Engineering Research Center of Bioprocess, MOE, School of Food & Biological Engineering, Hefei University of Technology, Hefei 230009, China
| | - Chao Yan
- Engineering Research Center of Bioprocess, MOE, School of Food & Biological Engineering, Hefei University of Technology, Hefei 230009, China
- Research Center for Biomedical and Health Science, School of Life and Health, Anhui Science & Technology University, Fengyang 233100, China
| | - Bangben Yao
- Engineering Research Center of Bioprocess, MOE, School of Food & Biological Engineering, Hefei University of Technology, Hefei 230009, China
- Anhui Province Institute of Product Quality Supervision & Inspection, Hefei 230051, P. R. China
| | - Jianfeng Lu
- Engineering Research Center of Bioprocess, MOE, School of Food & Biological Engineering, Hefei University of Technology, Hefei 230009, China
| | - Jianguo Xu
- Engineering Research Center of Bioprocess, MOE, School of Food & Biological Engineering, Hefei University of Technology, Hefei 230009, China
| | - Guodong Liu
- Research Center for Biomedical and Health Science, School of Life and Health, Anhui Science & Technology University, Fengyang 233100, China
| |
Collapse
|
4
|
Micheli L, Di Cesare Mannelli L, Del Bello F, Giannella M, Piergentili A, Quaglia W, Carrino D, Pacini A, Ghelardini C. The Use of the Selective Imidazoline I 1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity. Neurotherapeutics 2020; 17:1005-1015. [PMID: 32572830 PMCID: PMC7609613 DOI: 10.1007/s13311-020-00873-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Anti-cancer therapy based on the repeated administration of oxaliplatin is limited by the development of a disabling neuropathic syndrome with detrimental effects on the patient's quality of life. The lack of effective pharmacological approaches calls for the identification of innovative therapeutic strategies based on new targets. We focused our attention on the imidazoline I1 receptor (I1-R) and in particular on the selective I1-R agonist 2-(1-([1,1'-biphenyl]-2-yl)propan-2-yl)-4,5-dihydro-1H-imidazole) (carbophenyline). The purpose of this work was the preclinical evaluation of the efficacy of carbophenyline on oxaliplatin-induced neuropathic pain in mice. Carbophenyline, acutely per os administered (0.1-10 mg kg-1), induced a dose-dependent anti-hyperalgesic effect that was completely blocked by the pre-treatment with the I1-R antagonist 3 or the I1/α2 receptor antagonist efaroxan, confirming the I1-R-dependent mechanism. Conversely, pre-treatment with the I2-R antagonist BU224 did not block the anti-nociceptive effect evoked by carbophenyline. Repeated oral administrations of carbophenyline (1 mg kg-1) for 14 days, starting from the first day of oxaliplatin injection, counteracted the development of neuropathic pain in all behavioral tests (cold plate, Von Frey, and paw pressure tests) carried out 24 h after the last carbophenyline treatment on days 7 and 14. In the dorsal horn of the spinal cord, carbophenyline significantly decreased the oxaliplatin-induced astrocyte activation detected by immunofluorescence staining by the specific labelling with GFAP antibody. In conclusion, carbophenyline showed anti-neuropathic properties both after acute and chronic treatment with preventive effect against oxaliplatin-induced astrocyte activation in the spinal cord. Therefore, I1-R agonists emerge as a new class of candidates for the management of oxaliplatin-induced neuropathic pain.
Collapse
Affiliation(s)
- Laura Micheli
- Dept. of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy
| | - Lorenzo Di Cesare Mannelli
- Dept. of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Alessandro Piergentili
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Wilma Quaglia
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Donatello Carrino
- Department of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134, Florence, Italy
| | - Alessandra Pacini
- Department of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134, Florence, Italy
| | - Carla Ghelardini
- Dept. of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy
| |
Collapse
|
5
|
Vakarov SA, Gruzdev DA, Levit GL, Krasnov VP, Charushin VN, Chupakhin ON. Synthesis of enantiomerically pure 2-aryloxy carboxylic acids and their derivatives. RUSSIAN CHEMICAL REVIEWS 2019. [DOI: 10.1070/rcr4893] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Recent publications on the key preparation methods of the enantiomers of 2-aryloxy carboxylic acids are summarized and comparative analysis of the methods is given. The information is arranged according to the type of the starting compound, being classified into syntheses from enantiomerically pure chiral precursors and syntheses from prochiral precursors, which imply generation of an asymmetric centre in the substrate molecule. Data on the chemical resolution of racemic mixtures of the title compounds are addressed in a separate Section. Attention is focused on the preparation of practically valuable 2-aryloxy acids. Examples of biologically active derivatives of 2-aryloxy carboxylic acids are given.
The bibliography includes 121 references.
Collapse
|
6
|
Del Bello F, Bonifazi A, Giorgioni G, Quaglia W, Amantini C, Morelli MB, Santoni G, Battiti FO, Vistoli G, Cilia A, Piergentili A. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem 2019; 168:461-473. [DOI: 10.1016/j.ejmech.2019.02.056] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 02/15/2019] [Accepted: 02/18/2019] [Indexed: 12/24/2022]
|
7
|
Del Bello F, Bonifazi A, Giorgioni G, Petrelli R, Quaglia W, Altomare A, Falcicchio A, Matucci R, Vistoli G, Piergentili A. Novel muscarinic acetylcholine receptor hybrid ligands embedding quinuclidine and 1,4-dioxane fragments. Eur J Med Chem 2017; 137:327-337. [DOI: 10.1016/j.ejmech.2017.06.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 05/24/2017] [Accepted: 06/02/2017] [Indexed: 12/18/2022]
|
8
|
Giusepponi M, Cifani C, Micioni Di Bonaventura MV, Mattioli L, Hudson A, Diamanti E, Del Bello F, Giannella M, Mammoli V, Paoletti CD, Piergentili A, Pigini M, Quaglia W. Combined Interactions with I 1-, I 2-Imidazoline Binding Sites and α 2-Adrenoceptors To Manage Opioid Addiction. ACS Med Chem Lett 2016; 7:956-961. [PMID: 27774136 PMCID: PMC5066154 DOI: 10.1021/acsmedchemlett.6b00290] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Accepted: 09/08/2016] [Indexed: 11/29/2022] Open
Abstract
Tolerance and dependence associated with chronic opioid exposure result from molecular, cellular, and neural network adaptations. Such adaptations concern opioid and nonopioid systems, including α2-adrenoceptors (α2-ARs) and I1- and I2-imidazoline binding sites (IBS). Agmatine, one of the hypothesized endogenous ligands of IBS, targeting several systems including α2-ARs and IBS, proved to be able to regulate opioid-induced analgesia and to attenuate the development of tolerance and dependence. Interested in the complex pharmacological profile of agmatine and considering the nature of its targets, we evaluated two series of imidazolines, rationally designed to simultaneously interact with I1-/I2-IBS or I1-/I2-IBS/α2-ARs. The compounds showing the highest affinities for I1-/I2-IBS or I1-/I2-IBS/α2-ARs have been selected for their in vivo evaluation on opiate withdrawal syndrome. Interestingly, 9, displaying I1-/I2-IBS/α2-ARs interaction profile, appears more effective in reducing expression and acquisition of morphine dependence and, therefore, might be considered a promising tool in managing opioid addiction.
Collapse
Affiliation(s)
- Maria
Elena Giusepponi
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Carlo Cifani
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | | | - Laura Mattioli
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Alan Hudson
- Department
of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Eleonora Diamanti
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Fabio Del Bello
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Mario Giannella
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Corinne Dalila Paoletti
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Alessandro Piergentili
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Maria Pigini
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| |
Collapse
|
9
|
Del Bello F, Cilia A, Carrieri A, Fasano DC, Ghelardini C, Di Cesare Mannelli L, Micheli L, Santini C, Diamanti E, Giannella M, Giorgioni G, Mammoli V, Paoletti CD, Petrelli R, Piergentili A, Quaglia W, Pigini M. The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A
Receptor. ChemMedChem 2016; 11:2287-2298. [DOI: 10.1002/cmdc.201600383] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Revised: 08/30/2016] [Indexed: 11/12/2022]
Affiliation(s)
- Fabio Del Bello
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Antonio Cilia
- Recordati S.p.A.; Drug Discovery; via Civitali 1 20148 Milano (Italy)
| | - Antonio Carrieri
- Department of Pharmacy-Drug Science; University of Bari “Aldo Moro”; Via E. Orabona 4 70125 Bari Italy
| | - Domenico Claudio Fasano
- Department of Pharmacy-Drug Science; University of Bari “Aldo Moro”; Via E. Orabona 4 70125 Bari Italy
| | - Carla Ghelardini
- Department of Neuroscience, Psychology, Drug Research and; Child Health - Neurofarba - Pharmacology and Toxicology Section; University of Florence; Viale Pieraccini 6 50039 Firenze Italy
| | - Lorenzo Di Cesare Mannelli
- Department of Neuroscience, Psychology, Drug Research and; Child Health - Neurofarba - Pharmacology and Toxicology Section; University of Florence; Viale Pieraccini 6 50039 Firenze Italy
| | - Laura Micheli
- Department of Neuroscience, Psychology, Drug Research and; Child Health - Neurofarba - Pharmacology and Toxicology Section; University of Florence; Viale Pieraccini 6 50039 Firenze Italy
| | - Carlo Santini
- School of Science and Technology; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Eleonora Diamanti
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Mario Giannella
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Gianfabio Giorgioni
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Valerio Mammoli
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Corinne Dalila Paoletti
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Riccardo Petrelli
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Alessandro Piergentili
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Wilma Quaglia
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| | - Maria Pigini
- School of Pharmacy; Medicinal Chemistry Unit; University of Camerino; Via S. Agostino 1 62032 Camerino Italy
| |
Collapse
|
10
|
Mammoli V, Bonifazi A, Dal Ben D, Giannella M, Giorgioni G, Piergentili A, Pigini M, Quaglia W, Thomas A, Newman AH, Ferré S, Sanchez-Soto M, Keck TM, Del Bello F. A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus. ChemMedChem 2016; 11:1819-28. [PMID: 26990230 PMCID: PMC4993638 DOI: 10.1002/cmdc.201600022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Indexed: 01/08/2023]
Abstract
Over the years, the 2-substituted imidazoline nucleus has been demonstrated to be a bioversatile structural motif. In this study, novel imidazoline derivatives bearing a 3- and/or 4-hydroxy- or methoxy-substituted phenyl ring, linked by an ethylene bridge to position 2 of an N-benzyl- or N-phenethyl-substituted imidazoline nucleus, were prepared and studied against D2 -like receptor subtypes. Binding studies highlighted that a set of N-phenethylimidazoline compounds are selective for D4 over D2 and D3 receptors. In functional assays, the 3-methoxy-substituted derivative, endowed with the highest D4 affinity value, and its 3-hydroxy analogue behaved as partial agonists with low intrinsic efficacy and as competitive D4 antagonists when tested in the presence of the D2 -like receptor agonist quinpirole. Molecular docking analysis, performed using a homology model of the human D4 receptor developed using the X-ray crystal structure of the antagonist-bound human D3 receptor as a template, was in accordance with the binding results and provided useful information for the design of novel imidazoline D4 receptor ligands based on this new scaffold.
Collapse
Affiliation(s)
- Valerio Mammoli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Alessandro Bonifazi
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA
| | - Diego Dal Ben
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Gianfabio Giorgioni
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Alessandro Piergentili
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Wilma Quaglia
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Ajiroghene Thomas
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Amy H Newman
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA
| | - Sergi Ferré
- Integrative Neurobiology Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA
| | - Marta Sanchez-Soto
- Integrative Neurobiology Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA
| | - Thomas M Keck
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, 333 Cassell Drive, Baltimore, MD, 21224, USA
- Department of Chemistry & Biochemistry, Department of Biomedical & Translational Sciences, College of Science and Mathematics, Rowan University, 201 Mullica Hill Road, Glassboro, NJ, 08028, USA
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy.
| |
Collapse
|
11
|
Sączewski F, Kornicka A, Balewski Ł. Imidazoline scaffold in medicinal chemistry: a patent review (2012–2015). Expert Opin Ther Pat 2016; 26:1031-48. [DOI: 10.1080/13543776.2016.1210128] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
12
|
Zádori ZS, Fehér Á, Tóth VE, Al-Khrasani M, Köles L, Sipos S, Del Bello F, Pigini M, Gyires K. Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility. Dig Dis Sci 2016; 61:1512-23. [PMID: 26860509 DOI: 10.1007/s10620-015-4026-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Accepted: 12/27/2015] [Indexed: 12/09/2022]
Abstract
BACKGROUND Allyphenyline, a novel α2-adrenoceptor (AR) ligand, has been shown to selectively activate α2C-adrenoceptors (AR) and 5HT1A receptors, but also to behave as a neutral antagonist of α2A-ARs. We exploited this unique pharmacological profile to analyze the role of α2C-ARs and 5HT1A receptors in the regulation of gastric mucosal integrity and gastrointestinal motility. METHODS Gastric injury was induced by acidified ethanol in Wistar rats. Mucosal catalase and superoxide dismutase levels were measured by assay kits. The effect of allyphenyline on electrical field stimulation (EFS)-induced fundic and colonic contractions was determined in C57BL/6 mice. RESULTS Intracerebroventricularly injected allyphenyline (3 and 15 nmol/rat) dose dependently inhibited the development of mucosal damage, which was antagonized by ARC 239 (α2B/C-AR and 5HT1A receptor antagonist), (S)-WAY 100135 (selective 5HT1A receptor antagonist), and JP-1302 (selective α2C-AR antagonist). This protection was accompanied by significant elevation of mucosal catalase and superoxide dismutase levels. Allyphenyline (10(-9)-10(-5) M) also inhibited EFS-induced fundic contractions, which was antagonized by ARC 239 and (S)-WAY 100135, but not by JP-1302. Similar inhibition was observed in the colon; however, in this case only ARC 239 reduced this effect, while neither selective inhibition of α2C-ARs and 5HT1A receptors nor genetic deletion of α2A- and α2B-ARs influenced it. CONCLUSIONS Activation of both central α2C-ARs and 5HT1A receptors contributes to the gastroprotective action of allyphenyline in rats. Its inhibitory effect on fundic contractions is mediated by 5HT1A receptors, but neither α2-ARs nor 5HT1A receptors take part in its inhibitory effect on colonic contractility in mice.
Collapse
Affiliation(s)
- Zoltán S Zádori
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary
| | - Ágnes Fehér
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary
| | - Viktória E Tóth
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary
| | - Mahmoud Al-Khrasani
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary
| | - László Köles
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary
| | - Szabina Sipos
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032, Camerino, Italy
| | - Klára Gyires
- Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., Budapest, 1089, Hungary.
| |
Collapse
|
13
|
Caprioli G, Mammoli V, Ricciutelli M, Sagratini G, Ubaldi M, Domi E, Mennuni L, Sabatini C, Galimberti C, Ferrari F, Milia C, Comi E, Lanza M, Giannella M, Pigini M, Del Bello F. Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation. Eur J Pharmacol 2015; 769:219-24. [PMID: 26593429 DOI: 10.1016/j.ejphar.2015.11.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 11/12/2015] [Accepted: 11/13/2015] [Indexed: 11/20/2022]
Abstract
Tolerance to opioid administration represents a serious medical alert in different chronic conditions. This study compares the effects of the imidazoline compounds 1, 2, and 3 on morphine tolerance in an animal model of inflammatory pain in the rat. 1, 2, and 3 have been selected in that, although bearing a common scaffold, preferentially bind to α2-adrenoceptors, imidazoline I2 receptors, or both systems, respectively. Such compounds have been tested in vivo by measuring the paw withdrawal threshold to mechanical pressure after complete Freund's adjuvant injection. To determine the ligand levels in rat plasma, an HPLC-mass spectrometry method has been developed. All the compounds significantly reduced the induction of morphine tolerance, showing different potency and duration of action. Indeed, the selective imidazoline I2 receptor interaction (2) restored the analgesic response by maintaining the same time-dependent profile observed after a single morphine administration. Differently, the selective α2C-adrenoceptor activation (1) or the combination between α2C-adrenoceptor activation and imidazoline I2 receptor engagement (3) promoted a change in the temporal profile of morphine analgesia by maintaining a mild but long lasting analgesic effect. Interestingly, the kinetics of compounds in rat plasma supported the pharmacodynamic data. Therefore, this study highlights that both peculiar biological profile and bioavailability of such ligands complement each other to modulate the reduction of morphine tolerance. Based on these observations, 1-3 can be considered useful leads in the design of new drugs able to turn off the undesired tolerance induced by opioids.
Collapse
Affiliation(s)
- Giovanni Caprioli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Massimo Ricciutelli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Gianni Sagratini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Massimo Ubaldi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Esi Domi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Laura Mennuni
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Sabatini
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Galimberti
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Flora Ferrari
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Milia
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy; PhD program in Neuroscience, University of Milan-Bicocca, Italy
| | - Eleonora Comi
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy; PhD program in Neuroscience, University of Milan-Bicocca, Italy
| | - Marco Lanza
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy.
| |
Collapse
|
14
|
Ubaldi M, Del Bello F, Domi E, Pigini M, Nasuti C. Investigation of allyphenyline efficacy in the treatment of alcohol withdrawal symptoms. Eur J Pharmacol 2015; 760:122-8. [PMID: 25895641 DOI: 10.1016/j.ejphar.2015.04.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 03/31/2015] [Accepted: 04/02/2015] [Indexed: 10/23/2022]
Abstract
We have recently demonstrated that allyphenyline, behaving as α2C-adrenoceptor/serotonin 5-HT1A receptor agonist and α2A-adrenoceptor antagonist, in mice enhanced morphine analgesia, attenuated morphine withdrawal symptoms, showed significant antidepressant-like activity and was devoid of sedative side effects. Opioid and alcohol withdrawal shares several common neurobiological and molecular mechanisms. Therefore, in this study we expanded our analysis of the pharmacological properties of allyphenyline by investigating its ability to prevent the expression of somatic withdrawal signs, anxiety-like behavior and hyperlocomotion associated with chronic ethanol intoxication. Rats were subjected to induction of ethanol dependence via repeated daily intragastric ethanol (20%) administration for 4 consecutive days. Twelve hours after the last alcohol administration, somatic alcohol withdrawal signs were scored. Results revealed a significant expression of physical withdrawal signs that were not affected by intraperitoneal (i.p.) administration of allyphenyline at the doses of 0.05, 0.275 and 0.5 mg/kg. In contrast, allyphenyline (0.05 and 0.275 mg/kg i.p.) significantly reduced hyperanxiety-like behavior observed 6 days after alcohol intoxication as measured using the defensive burying test. Allyphenyline also reduced open field hyperlocomotor activity associated with alcohol withdrawal. Notably, the anxiolytic effect of the compound, as well as the already reported antidepressant action, was observed at very low doses, suggesting the involvement of its α2C-adrenoceptor/serotonin 5-HT1A receptor agonism. Therefore, the present investigation suggests that allyphenyline might represent an interesting pharmacological tool to investigate the potential of compounds exhibiting α2C-adrenoceptor/serotonin 5-HT1A receptor agonism and α2A-adrenoceptor antagonism in the treatment of hyperanxiety and hyperlocomotion occurring during alcohol withdrawal in dependent subjects.
Collapse
Affiliation(s)
- Massimo Ubaldi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy.
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032 Camerino, Italy.
| | - Esi Domi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, via S. Agostino 1, 62032 Camerino, Italy
| | - Cinzia Nasuti
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| |
Collapse
|
15
|
Del Bello F, Diamanti E, Giannella M, Mammoli V, Mattioli L, Titomanlio F, Piergentili A, Quaglia W, Lanza M, Sabatini C, Caselli G, Poggesi E, Pigini M. Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity. ACS Med Chem Lett 2013; 4:875-9. [PMID: 24900763 DOI: 10.1021/ml400232p] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Accepted: 07/22/2013] [Indexed: 01/22/2023] Open
Abstract
Opioid addiction is often characterized as a chronic relapsing condition due to the severe somatic and behavioral signs, associated with depressive disorders, triggered by opiate withdrawal. Since prolonged abstinence remains a major challenge, our interest has been addressed to such objective. Exploring multitarget interactions, the present investigation suggests that 3 or its (S)-enantiomer and 4, endowed with effective α2C-AR agonism/α2A-AR antagonism/5-HT1A-R agonism, or 7 and 9-11 producing efficacious α2C-AR agonism/α2A-AR antagonism/I2-IBS interaction might represent novel multifunctional tools potentially useful for reducing withdrawal syndrome and associated depression. Such agents, lacking in sedative side effects due to their α2A-AR antagonism, might afford an improvement over current therapies with clonidine-like drugs.
Collapse
Affiliation(s)
- Fabio Del Bello
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Eleonora Diamanti
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Laura Mattioli
- School of Pharmacy, Pharmacognosy
Unit, University of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Federica Titomanlio
- School of Pharmacy, Pharmacognosy
Unit, University of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Alessandro Piergentili
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Marco Lanza
- Pharmacology & Toxicology
Department, Rottapharm-Madaus, 20052 Monza,
Italy
| | - Chiara Sabatini
- Pharmacology & Toxicology
Department, Rottapharm-Madaus, 20052 Monza,
Italy
| | - Gianfranco Caselli
- Pharmacology & Toxicology
Department, Rottapharm-Madaus, 20052 Monza,
Italy
| | - Elena Poggesi
- Recordati S.pA., Drug Discovery, Via Civitali 1, 20148 Milano, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| |
Collapse
|